Compare Stocks: CMMB, BKHA, MGX, and ALGS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$4.86 -9.8%	$5.96	$3.98 ▼ $13.69	$33.66M	2.36	42,512 shs	67,552 shs
BKHA Black Hawk Acquisition	$6.01 -12.3%	$11.71	$5.47 ▼ $23.00	$28.45M	0.02	38,417 shs	13,438 shs
CMMB Chemomab Therapeutics	$1.27 -1.9%	$2.09	$1.05 ▼ $3.45	$9.35M	0.74	131,550 shs	9,080 shs
MGX Metagenomi	$0.78 -7.2%	$1.13	$0.77 ▼ $3.40	$31.93M	0.69	170,959 shs	163,663 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-9.83%	-8.99%	-3.76%	-15.33%	-53.18%
BKHA Black Hawk Acquisition	-12.26%	-47.88%	-49.11%	-51.26%	-45.88%
CMMB Chemomab Therapeutics	-1.94%	-8.33%	-52.26%	-18.91%	-62.57%
MGX Metagenomi	-7.24%	-21.60%	-31.83%	-36.77%	-74.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$4.86 -9.8%	$5.96	$3.98 ▼ $13.69	$33.66M	2.36	42,512 shs	67,552 shs
BKHA Black Hawk Acquisition	$6.01 -12.3%	$11.71	$5.47 ▼ $23.00	$28.45M	0.02	38,417 shs	13,438 shs
CMMB Chemomab Therapeutics	$1.27 -1.9%	$2.09	$1.05 ▼ $3.45	$9.35M	0.74	131,550 shs	9,080 shs
MGX Metagenomi	$0.78 -7.2%	$1.13	$0.77 ▼ $3.40	$31.93M	0.69	170,959 shs	163,663 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-9.83%	-8.99%	-3.76%	-15.33%	-53.18%
BKHA Black Hawk Acquisition	-12.26%	-47.88%	-49.11%	-51.26%	-45.88%
CMMB Chemomab Therapeutics	-1.94%	-8.33%	-52.26%	-18.91%	-62.57%
MGX Metagenomi	-7.24%	-21.60%	-31.83%	-36.77%	-74.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	692.18% Upside
BKHA Black Hawk Acquisition	1.00	Sell	N/A	N/A
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A
MGX Metagenomi	2.33	Hold	$6.00	665.31% Upside

Current Analyst Ratings Breakdown

Latest CMMB, BKHA, MGX, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/15/2026	BKHA Black Hawk Acquisition	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
9/25/2026	ALGS Aligos Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/22/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	13.85	N/A	N/A	$8.67 per share	0.56
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
MGX Metagenomi	$25.21M	1.17	N/A	N/A	$4.22 per share	0.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)

Latest CMMB, BKHA, MGX, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	MGX Metagenomi	-$0.6395	N/A	N/A	N/A	$2.58 million	N/A
11/6/2026	Q3 2026	CMMB Chemomab Therapeutics	-$0.01	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	ALGS Aligos Therapeutics	-$2.44	N/A	N/A	N/A	$4.85 million	N/A
10/6/2026	Q3 2026	BKHA Black Hawk Acquisition	N/A	$0.26	N/A	$0.26	N/A	N/A
8/20/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
BKHA Black Hawk Acquisition	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	6.41	6.41
MGX Metagenomi	N/A	4.50	4.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
BKHA Black Hawk Acquisition	N/A
CMMB Chemomab Therapeutics	46.05%
MGX Metagenomi	N/A

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
BKHA Black Hawk Acquisition	N/A
CMMB Chemomab Therapeutics	11.91%
MGX Metagenomi	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	82	6.24 million	5.76 million	No Data
BKHA Black Hawk Acquisition	2	4.15 million	N/A	N/A
CMMB Chemomab Therapeutics	12	7.25 million	6.38 million	Not Optionable
MGX Metagenomi	113	37.78 million	33.06 million	N/A

CMMB, BKHA, MGX, and ALGS Headlines

Recent News About These Companies

Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference

October 13, 2026 | globenewswire.com

Metagenomi updates hemophilia A gene editing program

September 22, 2026 | tipranks.com

Metagenomi (NASDAQ:MGX) Director Laurence Reid Purchases 20,000 Shares of Stock

September 12, 2026 | insidertrades.com

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026 | globenewswire.com

Metagenomi Therapeutics Inc MGX

August 25, 2026 | morningstar.comM

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

August 25, 2026 | prnewswire.com

MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript

August 20, 2026 | seekingalpha.com

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

August 11, 2026 | theglobeandmail.com

Metagenomi Therapeutics: Q2 Earnings Snapshot

August 10, 2026 | chron.com

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

August 10, 2026 | markets.businessinsider.com

Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2026 | zacks.com

MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript

July 20, 2026 | seekingalpha.com

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026 | globenewswire.com

Metagenomi Announces Board Changes and Shareholder Meeting Results

June 10, 2026 | tipranks.com

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

June 5, 2026 | prnewswire.com

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

May 28, 2026 | globenewswire.com

Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50

May 14, 2026 | msn.com

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates

May 14, 2026 | finance.yahoo.com

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 12, 2026 | markets.businessinsider.com

Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

May 11, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, BKHA, MGX, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$4.86 -0.53 (-9.83%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$4.89 +0.03 (+0.62%)

As of 10/16/2026 07:30 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Black Hawk Acquisition NASDAQ:BKHA

$6.01 -0.84 (-12.26%)

Closing price 10/16/2026 03:56 PM Eastern

Extended Trading

$6.00 -0.01 (-0.17%)

As of 10/16/2026 07:55 PM Eastern

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

Chemomab Therapeutics NASDAQ:CMMB

$1.26 -0.03 (-2.25%)

As of 10/16/2026 04:00 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Metagenomi NASDAQ:MGX

$0.78 -0.06 (-7.24%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.78 0.00 (-0.13%)

As of 10/16/2026 07:30 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, BKHA, MGX, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, BKHA, MGX, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, BKHA, MGX, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, BKHA, MGX, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Black Hawk Acquisition NASDAQ:BKHA

Chemomab Therapeutics NASDAQ:CMMB

Metagenomi NASDAQ:MGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, BKHA, MGX, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, BKHA, MGX, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, BKHA, MGX, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, BKHA, MGX, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Black Hawk Acquisition NASDAQ:BKHA

Chemomab Therapeutics NASDAQ:CMMB

Metagenomi NASDAQ:MGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools